Wakamoto Pharmaceutical Co., Ltd. (JP:4512)

:4512

4512

Wakamoto Pharmaceutical Co., Ltd.

RESEARCH TOOLSreports

Wakamoto Pharmaceutical Co., Ltd. (4512) Price & Analysis

0 Followers

4512 Stock Chart & Stats

¥286.00

-¥4.00(-1.79%)

At close: Jan 08 4:00 PM EST

¥286.00

-¥4.00(-1.79%)

Day’s Range― - ―

52-Week Range¥270.00 - ¥380.00

Previous CloseN/A

Volume100.70K

Average Volume (3M)65.94K

Market Cap

¥12.08B

Enterprise Value¥10.51B

Total Cash (Recent Filing)¥3.56B

Total Debt (Recent Filing)¥100.00M

Price to Earnings (P/E)7.1

Beta0.37

Next Earnings

May 15, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield1.06%

Share Statistics

EPS (TTM)10.05

Shares Outstanding34,838,326

10 Day Avg. Volume55,010

30 Day Avg. Volume65,936

Financial Highlights & Ratios

PEG Ratio-4.19

Price to Book (P/B)0.95

Price to Sales (P/S)1.41

P/FCF Ratio-10.55

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Strong Balance Sheet / Low LeverageA robust equity position and low debt-to-equity provide durable financial flexibility to fund product development, absorb demand shocks, and maintain distributor relationships without immediate external financing. This underpins long-term resilience and strategic optionality.

Stable Gross Profit MarginsStable gross margins indicate persistent product-level pricing power or controlled manufacturing costs in its OTC and prescription product lines. This protects core profitability and creates a foundation for margin recovery if operating expenses or mix are improved over months.

Recent Top-line Growth MomentumA ~16.8% reported revenue increase signals durable demand or improved distribution for consumer health products. Sustained revenue growth can help absorb fixed costs, support reinvestment, and enable scale benefits that improve margins over the medium term if conversion to cash is managed.

Bears Say

Negative Operating And Free Cash FlowPersistent negative operating and free cash flow erodes liquidity and forces reliance on cash reserves or external funding. Poor cash conversion undermines the firm's capacity to invest in R&D, maintain inventories, pay suppliers, or sustain dividends over the coming months without corrective action.

Declining Net Income And Negative EBIT MarginFalling net income and a negative EBIT margin point to structural operating inefficiencies or adverse product mix. Continued operating losses reduce retained earnings, constrain reinvestment, and weaken competitiveness unless cost structure or revenue mix is improved.

Liquidity Challenges Despite Strong EquityReported liquidity pressures, even with healthy equity, can limit working-capital flexibility and execution of growth initiatives. If cash is tied up or conversion fails, the company may face supplier constraints or postponed investments, hampering strategic plans in the medium term.

4512 FAQ

What was Wakamoto Pharmaceutical Co., Ltd.’s price range in the past 12 months?

Wakamoto Pharmaceutical Co., Ltd. lowest stock price was ¥270.00 and its highest was ¥380.00 in the past 12 months.

What is Wakamoto Pharmaceutical Co., Ltd.’s market cap?

Wakamoto Pharmaceutical Co., Ltd.’s market cap is ¥12.08B.

When is Wakamoto Pharmaceutical Co., Ltd.’s upcoming earnings report date?

Wakamoto Pharmaceutical Co., Ltd.’s upcoming earnings report date is May 15, 2026 which is in 39 days.

How were Wakamoto Pharmaceutical Co., Ltd.’s earnings last quarter?

Wakamoto Pharmaceutical Co., Ltd. released its earnings results on Feb 04, 2026. The company reported ¥10.05 earnings per share for the quarter, beating the consensus estimate of N/A by ¥10.05.

Is Wakamoto Pharmaceutical Co., Ltd. overvalued?

According to Wall Street analysts Wakamoto Pharmaceutical Co., Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Wakamoto Pharmaceutical Co., Ltd. pay dividends?

Wakamoto Pharmaceutical Co., Ltd. pays a Annually dividend of ¥3 which represents an annual dividend yield of 1.06%. See more information on Wakamoto Pharmaceutical Co., Ltd. dividends here

What is Wakamoto Pharmaceutical Co., Ltd.’s EPS estimate?

Wakamoto Pharmaceutical Co., Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Wakamoto Pharmaceutical Co., Ltd. have?

Wakamoto Pharmaceutical Co., Ltd. has 34,838,326 shares outstanding.

What happened to Wakamoto Pharmaceutical Co., Ltd.’s price movement after its last earnings report?

Wakamoto Pharmaceutical Co., Ltd. reported an EPS of ¥10.05 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Wakamoto Pharmaceutical Co., Ltd.?

Currently, no hedge funds are holding shares in JP:4512

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Wakamoto Pharmaceutical Co., Ltd.

Wakamoto Pharmaceutical Co., Ltd. manufactures and sells ethical and non-prescription drugs in Japan. The company offers Strong Wakamoto, a gastrointestinal drug for digestion, intestinal regulation, and nutritional supplementation. It also provides AVANTBISE oral tablets, a supplement of bacteria to restore the balance of oral flora; and medicated toothpaste. The company was formerly known as Society for Nutrition and Raising Children Co., Ltd. and changed its name to Wakamoto Pharmaceutical Co., Ltd. in July 1943. Wakamoto Pharmaceutical Co., Ltd. was founded in 1929 and is headquartered in Tokyo, Japan.